Updated:
Sapphiros
Sapphiros is a privately held consumer diagnostics company backed by KKR and Neoenta. It brings together advanced science, intelligent design and scalable...
Sapphiros
Sapphiros is a privately held consumer diagnostics company backed by KKR and Neoenta. It brings together advanced science, intelligent design and scalable technology to make high-quality diagnostic testing accessible to all. Sapphiros was founded to close the gaps in health testing revealed during the Covid-19 pandemic. Its portfolio includes novel sample collection, next generation diagnostics, and extreme volume manufacturing.
General information
Firm type
Private Equity
Year founded
2021
Location
Region
North America
Country
United States
City
Boston
Corporate office
135 William T Morrissey Blvd, Suite P101, Boston, MA 02125, United States
Additional offices
Cambridge, United Kingdom · Hove, United Kingdom · Saffron Walden, United Kingdom
Principals
Namal Nawana
Founder
Mark Gladwell
Chief Executive Officer, President & Board Member
Dawn Hudson
Board Member
Carrie Eglinton Manner
Board Member
Ali Satvat
Board Member
Anuv Ratan
Board Member
Jackson McAdam
Chief Financial Officer
Teresa Abraham
Vice President of Scientific & Technical Affairs
Andy Garfield
Chief Operations Officer
Hannah Slack
HR Director
KC McGrath
Vice President, Product Strategy
Ryan Schmidt
General Manager, Commercial
Mike Robbat
General Counsel
Peter Stebbins
Vice President and General Manager, Satio
Sector focus
Frequently asked questions
What does Sapphiros actually own and operate?
Sapphiros operates four disclosed subsidiaries: Satio, developing a consumer wearable diagnostic patch; GrapheneDx, building a handheld at-home testing device; a Cambridge-based molecular-detection unit focused on isothermal nucleic-acid amplification; and a Hove-based materials and manufacturing center producing printed electronics and lateral-flow tests. The firm controls its own UK manufacturing lines rather than outsourcing production.
Who runs Sapphiros, and who makes investment decisions?
Sapphiros does not publicly disclose its management team or investment committee on its website. Corporate filings show the US entity (Sapphiros LLC) and UK entity (Sapphiros UK Ltd) are registered but do not list directors or principals in publicly available materials. Decision-making structure is therefore unconfirmed from primary sources.
Where does Sapphiros manufacture its diagnostics, and at what scale?
Manufacturing is concentrated at the Hove, UK facility, which is described as a center of excellence for extreme-volume lateral-flow production and printed electronics. The firm states the facility has a capacity of five billion units annually, making it one of the highest-volume diagnostics manufacturing sites publicly disclosed by a private platform.
What types of diagnostics does Sapphiros focus on?
The portfolio spans consumer-based patch diagnostics (Satio), molecular at-home testing (GrapheneDx), ultra-rapid isothermal amplification for infectious disease and genetic testing (Cambridge), and lateral-flow and printed-electronics formats (Hove). The common thread is low-cost, scalable platforms intended for both advanced and resource-limited settings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: